Kevin Joseph Fitzgerald
Cso & Evp, Head Of Research at Alnylam Pharmaceuticals, Inc. (ALNY)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $10.7M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 2921,831 held (−0%) | $319.03 | $9K | -27.1% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 2821,803 held (−0%) | $320.01 | $9K | -27.3% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 5921,744 held (−0%) | $320.81 | $19K | -27.5% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 7921,665 held (−0%) | $321.82 | $25K | -27.7% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 9621,569 held (−0%) | $323.01 | $31K | -28.0% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 21021,359 held (−1%) | $323.84 | $68K | -28.1% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 7521,284 held (−0%) | $324.88 | $24K | -28.4% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 5721,227 held (−0%) | $325.67 | $19K | -28.6% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 12421,103 held (−1%) | $321.81 | $40K | -27.7% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 23320,870 held (−1%) | $323.25 | $75K | -28.0% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 14820,722 held (−1%) | $324.60 | $48K | -28.3% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 15320,569 held (−1%) | $326.24 | $50K | -28.7% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 4725,063 held (−0%) | $323.62 | $15K | -28.1% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 9024,973 held (−0%) | $324.65 | $29K | -28.3% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 25824,715 held (−1%) | $325.63 | $84K | -28.5% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 39224,323 held (−2%) | $326.81 | $128K | -28.8% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 32923,994 held (−1%) | $327.67 | $108K | -29.0% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 10023,894 held (−0%) | $328.71 | $33K | -29.2% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 17023,724 held (−1%) | $329.71 | $56K | -29.4% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 8123,643 held (−0%) | $330.85 | $27K | -29.7% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 9423,549 held (−0%) | $331.93 | $31K | -29.9% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 3723,512 held (−0%) | $332.64 | $12K | -30.1% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 28923,223 held (−1%) | $316.55 | $91K | -26.5% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 28222,941 held (−1%) | $318.62 | $90K | -27.0% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 72222,219 held (−3%) | $320.51 | $231K | -27.4% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 35921,860 held (−2%) | $321.58 | $115K | -27.6% |
| Feb 17SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 1,95923,305 held (−8%) | $310.08 | $607K | -25.0% |
| Feb 17SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 2,04121,264 held (−9%) | $331.96 | $678K | -29.9% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 3925,025 held (−0%) | $353.95 | $14K | -34.3% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 4224,983 held (−0%) | $355.16 | $15K | -34.5% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 4124,942 held (−0%) | $356.09 | $15K | -34.7% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 9624,846 held (−0%) | $357.17 | $34K | -34.9% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 12324,723 held (−0%) | $358.18 | $44K | -35.0% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 8524,638 held (−0%) | $359.14 | $31K | -35.2% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 15524,483 held (−1%) | $360.22 | $56K | -35.4% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 9824,385 held (−0%) | $361.45 | $35K | -35.6% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 7324,312 held (−0%) | $362.38 | $26K | -35.8% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 4724,265 held (−0%) | $363.55 | $17K | -36.0% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 19924,066 held (−1%) | $364.83 | $73K | -36.2% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 22023,846 held (−1%) | $365.56 | $80K | -36.3% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 5023,796 held (−0%) | $366.41 | $18K | -36.5% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 4123,755 held (−0%) | $367.40 | $15K | -36.7% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 9223,663 held (−0%) | $368.62 | $34K | -36.9% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 4023,623 held (−0%) | $369.48 | $15K | -37.0% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 1923,604 held (−0%) | $370.87 | $7K | -37.3% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 223,602 held (−0%) | $372.46 | $745 | -37.5% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 1423,588 held (−0%) | $374.44 | $5K | -37.9% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 1923,569 held (−0%) | $375.65 | $7K | -38.1% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 1523,554 held (−0%) | $377.82 | $6K | -38.4% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 19723,357 held (−1%) | $367.52 | $72K | -36.7% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 56222,795 held (−2%) | $368.76 | $207K | -36.9% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 64422,151 held (−3%) | $370.00 | $238K | -37.1% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 48521,666 held (−2%) | $371.24 | $180K | -37.3% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 28021,386 held (−1%) | $372.93 | $104K | -37.6% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 12221,264 held (−1%) | $374.33 | $46K | -37.8% |
| Nov 19SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 8,16825,224 held (−24%) | $449.00 | $3.7M | -48.2% |
| Nov 19SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 9625,128 held (−0%) | $450.09 | $43K | -48.3% |
| Nov 19SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 12924,999 held (−1%) | $451.51 | $58K | -48.5% |
| Nov 19SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 36824,631 held (−1%) | $455.24 | $168K | -48.9% |
| Nov 19SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 36424,267 held (−1%) | $456.25 | $166K | -49.0% |
| Nov 19SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 26224,005 held (−1%) | $457.39 | $120K | -49.1% |
| Nov 19SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 79423,211 held (−3%) | $458.41 | $364K | -49.2% |
| Nov 19SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 62222,589 held (−3%) | $459.89 | $286K | -49.4% |
| Nov 19SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 70721,882 held (−3%) | $460.84 | $326K | -49.5% |
| Nov 19SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 32321,559 held (−1%) | $461.96 | $149K | -49.6% |
| Nov 19SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 29521,264 held (−1%) | $463.08 | $137K | -49.8% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 9627,576 held (−0%) | $446.53 | $43K | -47.9% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 4727,529 held (−0%) | $447.92 | $21K | -48.1% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 15027,379 held (−1%) | $448.77 | $67K | -48.2% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 20727,172 held (−1%) | $449.79 | $93K | -48.3% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 44926,723 held (−2%) | $450.81 | $202K | -48.4% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 27626,447 held (−1%) | $451.86 | $125K | -48.5% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 55525,892 held (−2%) | $452.69 | $251K | -48.6% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 27325,619 held (−1%) | $453.77 | $124K | -48.7% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 20325,416 held (−1%) | $454.84 | $92K | -48.8% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 6025,356 held (−0%) | $455.82 | $27K | -49.0% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 12225,234 held (−0%) | $457.43 | $56K | -49.1% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 325,231 held (−0%) | $457.64 | $1K | -49.2% |
- Sell
Cso & Evp, Head Of Research Kevin Joseph Fitzgerald sold $9K of ALNY at $319.03 — pre-scheduled 10b5-1 plan sale.
- Sell
Cso & Evp, Head Of Research Kevin Joseph Fitzgerald sold $9K of ALNY at $320.01 — pre-scheduled 10b5-1 plan sale.
- Sell
Cso & Evp, Head Of Research Kevin Joseph Fitzgerald sold $19K of ALNY at $320.81 — pre-scheduled 10b5-1 plan sale.
- Sell
Cso & Evp, Head Of Research Kevin Joseph Fitzgerald sold $25K of ALNY at $321.82 — pre-scheduled 10b5-1 plan sale.
- Sell
Cso & Evp, Head Of Research Kevin Joseph Fitzgerald sold $31K of ALNY at $323.01 — pre-scheduled 10b5-1 plan sale.
- Sell
Cso & Evp, Head Of Research Kevin Joseph Fitzgerald sold $68K of ALNY at $323.84 — pre-scheduled 10b5-1 plan sale.